PRECLINICAL ALZHEMER'S DISEASE PREDICTS POST-STROKE DEMENTIA

项目1将测试中风后痴呆是临床前阿尔茨海默病的一个功能的假设 （AD）。从这一假设的预测是，中风后痴呆症将不成比例的代表 与无临床前AD的卒中个体相比， 该项目的具体目标是： 1.在3.5年内，入组240名年龄≥ 65岁的老年人，因急性 缺血性卒中并获得基线人口统计学数据、病史、神经系统状态 神经心理学评估，卒中前认知和功能状态，以及项目2的血液 （血浆）和项目4（DMA）。 2.在该住院队列中，获得磁共振成像（MRI）以表征脑 [11 C]苯并噻唑淀粉样蛋白的缺血性病变和正电子发射断层扫描（PET） 示踪剂，匹兹堡化合物B（PI B），以确定是否存在临床前AD（如 由阳性PIB扫描定义）。 3.出院后每三个月与患者及其家属保持电话联系， 监控并发事件并保持合规性。 4.卒中后一年，使用临床核心临床和神经心理学量表评估所有患者 并推导出与基线PIB状态相关的临床痴呆评级（CDR）（CDR > 0.5将被视为痴呆症的证据）。 5.卒中后1年进行MRI，以评价潜在的新发缺血性病变;采集血液用于血浆分析 生物标志物（项目2）;招募患者进入项目3;并每年对所有患者进行临床和 进行认知评估，并获得自愿同意进行尸检。 该项目直接解决了项目资助的总体目标，以表征临床前AD。它 进一步解决了为什么痴呆症会发生在一些（但不是所有）中风患者身上这一尚未解决的问题。 该项目使用所有核心的资源。它还与每个单独的项目进行交互

Project 1 will test the hypothesis that poststroke dementia is a function of preclinical Alzheimer's disease (AD). The prediction from this hypothesis is that poststroke dementia will be disproportionately represented in stroke individuals with preclinical AD in comparison with stroke individuals without preclinical AD. The Specific Aims of the project are to: 1. Over 3.5 years, enroll a cohort of 240 older adults, age 65 years and older, hospitalized with acute ischemic stroke and obtain baseline demographic data, medical history, neurological status, neuropsychological evaluation, prestroke cognitive and functional status, and blood for Project 2 (plasma) and Project 4 (DMA). 2. In this hospitalized cohort, obtain magnetic resonance imaging (MRI) to characterize cerebral ischemic lesions and positron emission tomography (PET) with the [11C]benzothiazole amyloid tracer, Pittsburgh Compound B (PIB), to determine the presence or absence of preclinical AD (as defined by a positive PIB scan). 3. Every three months after discharge, maintain telephone contact with the patient and their families to monitor intercurrent events and maintain compliance. 4. One year poststroke, assess all patients with the Clinical Core clinical and neuropsychological batteries and derive a Clinical Dementia Rating (CDR) for correlation with baseline PIB status (CDR > 0.5 will be considered evidence for dementia). 5. Obtain MRI one year poststroke to evaluate potential new ischemic lesions; obtain blood for plasma biomarkers (Project 2); enroll patients into Project 3; and follow all patients annually with clinical and cognitive assessments and obtain voluntary consent for autopsy. This project directly addresses the overall aim of the program project grant, to characterize preclinical AD. It further addresses the unresolved issue of why dementia occurs in some, but not all, individuals with stroke. This project uses resources from all Cores. It also interacts with each of the individual projects